MedPath

Rifapentine

Generic Name
Rifapentine
Brand Names
Priftin
Drug Type
Small Molecule
Chemical Formula
C47H64N4O12
CAS Number
61379-65-5
Unique Ingredient Identifier
XJM390A33U
Background

Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

Indication

For the treatment of pulmonary tuberculosis.

Associated Conditions
Active Tuberculosis, Late phase Tuberculosis
Clinical Trials
Related News

Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

Not Applicable
Completed
Conditions
HIV/AIDS
Tuberculosis
Hepatitis
Addiction
Opioid Dependence
Interventions
First Posted Date
2017-03-24
Last Posted Date
2024-10-04
Lead Sponsor
Yale University
Target Recruit Count
1702
Registration Number
NCT03089983
Locations
🇲🇾

Kajang Prison, Kajang, Selangor, Malaysia

Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals

Phase 3
Completed
Conditions
HIV
Tuberculosis
Interventions
First Posted Date
2016-12-02
Last Posted Date
2019-10-30
Lead Sponsor
The Aurum Institute NPC
Target Recruit Count
4027
Registration Number
NCT02980016
Locations
🇿🇦

The Aurum Institute NPC, Johannesburg, Gauteng, South Africa

The Correlate of Risk Targeted Intervention Study

Phase 2
Conditions
Tuberculosis
Interventions
First Posted Date
2016-04-12
Last Posted Date
2018-12-24
Lead Sponsor
University of Cape Town
Target Recruit Count
2927
Registration Number
NCT02735590
Locations
🇿🇦

Stellenbosch Immunology Research Group, Cape Town, Western Cape, South Africa

🇿🇦

Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, KwaZulu-Natal, South Africa

🇿🇦

South African Tuberculosis Vaccine Initiative (SATVI), Worcester, Western Cape, South Africa

and more 1 locations

Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

Phase 1
Completed
Conditions
Tuberculosis
Interventions
Dietary Supplement: Pyridoxine (vitamin B6)
First Posted Date
2016-01-08
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
50
Registration Number
NCT02651259
Locations
🇿🇼

Harare Family Care CRS, Harare, Zimbabwe

🇲🇼

Malawi CRS, Lilongwe, Central Malawi, Malawi

🇭🇹

Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti

and more 2 locations

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Phase 3
Conditions
Tuberculosis
Interventions
Dietary Supplement: Pyridoxine
First Posted Date
2015-09-30
Last Posted Date
2017-03-01
Lead Sponsor
Centers for Disease Control and Prevention
Target Recruit Count
60
Registration Number
NCT02563327
Locations
🇺🇬

Mulago Hospital, Kampala, Uganda

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Phase 3
Completed
Conditions
Tuberculosis
Interventions
Drug: control
First Posted Date
2015-04-08
Last Posted Date
2024-12-04
Lead Sponsor
Centers for Disease Control and Prevention
Target Recruit Count
2516
Registration Number
NCT02410772
Locations
🇨🇳

TBTC Site 36 TB and Chest Service of Hong Kong, China, Hong Kong, China

🇰🇪

TBTC Site 02/ ACTG 12501 Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS, Kericho, Kericho County, Kenya

🇿🇦

TBTC Site 01/ACTG Site 8950 FAM CRU, Parow Valley, Western Cape, South Africa

and more 30 locations

PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

Phase 1
Completed
Conditions
Tuberculosis
Interventions
First Posted Date
2014-08-13
Last Posted Date
2019-09-06
Lead Sponsor
Global Alliance for TB Drug Development
Target Recruit Count
32
Registration Number
NCT02216331
Locations
🇺🇸

Celerion (MDS Pharma Services), Lincoln, Nebraska, United States

Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan

Phase 3
Conditions
Latent Tuberculosis Infection
Interventions
First Posted Date
2014-08-05
Last Posted Date
2016-12-15
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
283
Registration Number
NCT02208427
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

Phase 1
Completed
Conditions
Tuberculosis
Interventions
Drug: EFZ EMT TDF
First Posted Date
2012-09-21
Last Posted Date
2015-02-27
Lead Sponsor
Sanofi
Target Recruit Count
25
Registration Number
NCT01690403
Locations
🇺🇸

Investigational Site Number 840001, Buffalo, New York, United States

Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults

Phase 1
Completed
Conditions
Tuberculosis
Interventions
First Posted Date
2012-04-10
Last Posted Date
2021-11-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
44
Registration Number
NCT01574638
Locations
🇺🇸

UCSD Antiviral Research Center CRS, San Diego, California, United States

🇺🇸

Chapel Hill CRS, Chapel Hill, North Carolina, United States

🇺🇸

Johns Hopkins University CRS, Baltimore, Maryland, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy